Psoriasis

Risankizumab outperformed other biologics in real-world psoriasis treatment, achieving higher PASI 90/100 rates and patient satisfaction.

The key opinion leaders examine a case study of a 42-year-old male patient, detailing the process of treatment selection and shared decision-making that led to improved outcomes.

Medical experts specializing in plaque psoriasis offer a comprehensive overview of the current treatment landscape, its evolution, and the disease's psychological and physical impacts.

Researchers found the assessment accounted for those with moderate impact, allowing clinicians to create improved treatment plans for patients.

Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.

Sara Osborne, a fourth-year medical student and the lead author on the study, spoke with Dermatology Times on key findings and explain the need for further investigation.

A recent review found that disparities and barriers, such as income, age, and location, can impede patient access to necessary care.

Omar Noor, MD, and a patient with psoriasis share their unique perspectives on moderate to severe plaque psoriasis treatment with tildrakizumab.

Weekend treatment with cyclosporine may be beneficial for patients with moderate to severe psoriasis, according to a new study.

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

The results indicated improvement in PASI and sPGA scores as well as improvement in quality of life indicators in adults with moderate to severe psoriasis.

Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.

Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.

The treatment is the first IL-17 targeting topical therapy being developed for less severe cases of psoriasis.

This research indicates that psychological well-being serves a key role in the management of psoriatic disease.

The study not only showed success for patients with severe psoriasis, but also suggested it may be worth trying before other biologics.

Based on these findings, Innovent plans to submit a New Drug Application to the Center for Drug Evaluation of National Medical Product Administration.

Researchers from NYU Langone recently published a study clarifying the role of HIF-1-alpha in inflammation and psoriasis, which has been unclear until now.

A study out of Japan found some biologics used to treat psoriasis may require higher dose escalation than others.

Ayesha Patrick, the founder of Sistas With Psoriasis, spoke with Dermatology Times about her involvement in AbbVie's Clearly Me campaign.

Clearly Me uses portraiture to spotlight the journeys of psoriasis patients Katie Lowes, DaQuane Cherry, Ayesha Patrick, and Joanna “JoJo” Pomerantz.

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Mark Lebwohl, MD, and Saakshi Khattri, MD, discuss the evolving landscape of plaque psoriasis treatments over the past year.

Last week, the FDA approved an sBLA for Sandoz’s adalimumab-adaz in various strengths, including 10 mg/0.1 mL, 20 mg/0.2 mL, and 80 mg/0.8 mL.

A poster from the 2024 American Psychiatric Association Annual Meeting delved into the relationship between MDD and various dermatologic conditions.